文献速递浆细胞疾病

BCL7A缺失赋予多发性骨髓瘤IRF4转录活性与细胞生长能力

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

该研究通过全基因组测序发现62%的多发性骨髓瘤患者存在BCL7A基因5'非翻译区和/或内含子1突变,RNA测序提示多数患者BCL7A表达缺失。BCL7A失活使骨髓瘤细胞在体外和体内呈高增殖表型,其异位表达显著降低细胞活力,提示BCL7A具有抑癌功能;BCL7A与IRF4直接蛋白互作并限制其DNA结合活性,BCL7A缺失增强IRF4相关细胞因子表达并降低线粒体代谢和活性氧水平。

要点

  • 62%的多发性骨髓瘤患者存在BCL7A基因5'非翻译区和/或内含子1突变。
  • BCL7A失活导致骨髓瘤细胞体外和体内高增殖,异位表达显著降低细胞活力。
  • BCL7A与IRF4直接蛋白互作并限制其DNA结合活性,BCL7A缺失增强IRF4相关细胞因子表达。

核心结论

  • BCL7A缺失提供了允许IRF4介导的转录活性及多发性骨髓瘤细胞生长和生存所需的分子改变。

研究设计与样本

  • 研究采用全基因组测序、RNA测序及多发性骨髓瘤细胞系功能实验,样本来自多发性骨髓瘤患者和正常浆细胞。

主要发现

  • 全基因组测序显示62%的多发性骨髓瘤患者BCL7A基因5'非翻译区和/或内含子1发生突变。
  • RNA测序数据提示与正常浆细胞相比,大多数多发性骨髓瘤患者BCL7A表达缺失。
  • BCL7A失活使一组多发性骨髓瘤细胞系在体外和体内呈高增殖表型,而异位表达显著降低细胞活力。
  • BCL7A与IRF4直接蛋白互作并限制其DNA结合活性,BCL7A缺失增强IRF4相关细胞因子表达并降低线粒体代谢和活性氧水平。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a complex hematological malignancy characterized by genomic changes and transcriptomic dysregulation. Initial exome sequencing approaches have failed to identify any single, frequent (>25%) mutation in the coding genome. However, using whole-genome sequencing, we found that one of the genomic regions most frequently mutated (62% of the patients with MM) was the 5' untranslated region and/or intron 1 of the BCL7A gene. RNA-sequencing data from a large cohort suggest a loss of BCL7A expression in a large majority of patients with MM as compared with normal plasma cells. BCL7A loss of function in a panel of MM cell lines led to a highly proliferative phenotype in vitro and in vivo, whereas its ectopic expression significantly reduced cell viability, suggesting a tumor suppressor function for BCL7A in MM. We studied the cellular and molecular effects of BCL7A loss and observed that it endows myeloma cells with proliferative potential in cooperation with the plasma cell-defining transcription factor IRF4. BCL7A is involved in a direct protein-protein interaction with IRF4, limiting its DNA-binding activity. Loss of BCL7A thus enhances the expression of IRF4-associated cytokines and reduces mitochondrial metabolism and reactive oxygen species levels. Our study therefore suggests that BCL7A loss provides the necessary molecular change to allow IRF4-mediated transcriptional activity and MM cell growth and survival.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chakraborty C, Talluri S, Binder M, et al. Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma. Blood. 2025. PMID: 40090008. doi:10.1182/blood.2024026588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。